Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.
Nazli Dizman, MD, hematology/oncology fellow at MD Anderson Cancer Center, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma (RCC) and what suggestions she has for improvements.
At the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Annual Meeting, Dizman and colleagues presented research on adherence to the ASCO language of respect guidelines among patients with RCC. These guidelines include:
Here, Dizman also discusses how she envisions the continued promotion and implementation of respectful language in oncology research and communication.
Transcription:
0:09 | The guidelines are very well written, detailed with examples, and not available on the website of ASCO. I think as a guideline, they are sufficient, but I do think that we need to raise more awareness about their existence and how we should be cognizant about really prioritizing the patient-centered approach. I do believe that those are small steps that could easily be taken and be fixed by just paying attention to it. So, I am hoping that we could raise awareness for people to read through the guidelines and pay attention in the future.
0:53 | We could see more guidelines from other institutions or societies, highlighting the importance, so language of respect, perhaps journal submissions could also include a few sentences prioritizing this respect of language. Aside from just in written communications, I think on the podiums in conference presentations, ensuring the review of the material that is going to be presented from this standpoint would also be helpful.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More